

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/149492> since

Published version:

DOI:10.1016/j.amjcard.2014.07.081

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Am J Cardiol. 2014 Nov 1;114(9):1447-1455. doi: 10.1016/j.amjcard.2014.07.08

The definitive version is available at:

La versione definitiva è disponibile alla URL:

<http://www.sciencedirect.com/science/article/pii/S0002914914016038#>

Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation

Q2 Francesca Giordana, MD^{a,*}, Fabrizio D'Ascenzo, MD^a, Freek Nijhoff, MD^b, Claudio Moretti, MD^a,
Maurizio D'Amico, MD^a, Giuseppe Biondi Zoccai, MD^c, Jan Malte Sinning, MD^d,
George Nickenig, MD^d, Nicolas M. Van Mieghem, MD^e, Adelaide Chieffo, MD^f,
Nicolas Dumonteil, MD^g, Didier Tchetché, MD^h, Israel M. Barbash, MDⁱ, Ron Waksman, MDⁱ,
Augusto D'Onofrio, MD^j, Thierry Lefevre, MD^k, Thomas Pilgrim, MD^l, Nicolas Amabile, MD^m,
Pablo Codner, MD^{n,o}, Ran Kornowski^{n,o}, Ze Yie Yong, MD^p, Jan Baan, MD^p, Antonio Colombo, MD^q,
Azeem Latib, MD^q, Stefano Salizzoni, MD^r, Pierluigi Omedè, MD^a, Federico Conrotto, MD^a,
Q1 Michele La Torre, MD^r, Sebastiano Marra, MD^a, Mauro Rinaldi^r, and Fiorenzo Gaita^a

Q4 The aim of this study was to identify predictors of 30-day and midterm mortality after transcatheter aortic valve implantation (TAVI) by means of a systemic review. TAVI was demonstrated to be safe and efficacious in patients with severe aortic stenosis. An accurate estimation of procedural risk of these patients represents an actual challenge. The PubMed and Cochrane Collaboration databases were systematically searched for studies reporting on the incidence and independent predictors of 30-day and midterm mortality. Adverse events were pooled with random effect, whereas independent predictors are reported as odds ratios (ORs) with 95% confidence intervals (CIs). A total of 25 studies with 8,874 patients were included (median age 82.5 – 1.5 years, 54.6% women). At 30 days, 7.5% of patients (n = 663) died. At midterm follow-up (median 365 days, interquartile range 267 to 365 days), the cumulative mortality rate was 21.6% (n = 1,917). Acute kidney injury (AKI) stage ≥2 (OR 18.0, 95% CI 6.3 to 52), preprocedural hospitalization for heart failure (OR 9.4, 95% CI 2.6 to 35), periprocedural acute myocardial infarction (OR 8.5, 95% CI 2.6 to 33.5), and increased pro-brain natriuretic peptide (pro-BNP) levels (OR 5.4, 95% CI 1.7 to 16.5) were the most important independent predictors of 30-day mortality. Increased pro-BNP levels (OR 11, 95% CI 1.5 to 81), AKI stage 3 (OR 6.8, 95% CI 2.6 to 15.7), left ventricular ejection fraction <30% (OR 6.7, 95% CI 3.5 to 12.7), and periprocedural acute myocardial infarction (OR 6.5, 95% CI 2.3 to 18.1) represented the predictors of midterm mortality. In conclusion, in this large meta-analysis of patients undergoing TAVI, we found that high pro-BNP levels and postprocedural AKI were the strongest independent predictors of both 30-day and 1-year mortality. These findings may contribute to a better understanding of the risk assessment process of patients undergoing TAVI. 2014 Elsevier Inc. All rights reserved. (Am J Cardiol 2014;--:--e--)

Despite being one of the most important aspects of transcatheter aortic valve implantation (TAVI) practice, adequate patient selection represents a clinical issue not fully resolved. Allocating transcatheter treatment to the correct patients, reasonably expected to benefit in terms of functionality and survival, is essential to avoid unnecessary

high-risk procedures with accompanying costs.^{1e4} However, assessment of patient eligibility is often complex because of the extensive co-morbidity encountered in candidates for TAVI, rendering it difficult to estimate whether a beneficial treatment effect can be expected in individual patients, especially because surgical risk scores (EuroSCORE and

Q2 ^aDivision of Cardiology, Department of Internal Medicine and ^dDivision of Cardio-Surgery, Città della Salute e della Scienza, University of Turin, Turin, Italy; ^bDepartment of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands; ^cDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; ^dMedizinische Klinik und Poliklinik II, Universitätsklinikum, Bonn, Germany; ^eDepartment of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; ^fSan Raffaele Scientific Institute, Milan, Italy; ^gHôpital Rangueil, Toulouse, France; ^hClinique Pasteur, Toulouse, France; ⁱInterventional Cardiology, Washington Hospital Center, Washington, DC; ^jInvasive Cardiology Laboratory, Cardiology Division, University of Padova, Padova, Italy; ^kInstitut Cardiovasculaire Paris Sud, Massy, France; ^lDepartment of Cardiology, Swiss

Cardiovascular Center, Bern University Hospital, Bern, Switzerland; ^mDepartment of Cardiology, Centre Marie Lannelongue, Le Plessis-Robinson, France; ⁿCardiology, Beilinson Hospital, Rabin Medical Center, Petach-Tikva, Israel; ^oTel-Aviv University, Sackler Faculty of Medicine, Tel-Aviv, Israel; ^pDepartment of Cardiology and Cardio-Thoracic Surgery, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands; and ^qInterventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy. Manuscript received April 25, 2014; revised manuscript received and accepted July 30, 2014.

See page 7 for disclosure information.

*Corresponding author: Tel: (p39) 0116335570; fax: (p39) 0116336769.

E-mail address: francy.giordana@gmail.com (F. Giordana).




Figure 1. Study selection.

Society of Thoracic Surgery score) are less reliable in patients undergoing TAVI.^{5e7} The primary challenge to improve patient selection and counseling is hindered by the search for accurate and validated risk factors for mortality after TAVI. The investigation of predictors of mortality may yield helpful tools that could facilitate decision making of the heart team. Contemporary literature falls short in addressing this issue, despite the availability of numerous publications, as the knowledge on predictors of mortality is fragmentary. Meta-analyses have currently been performed only for reporting the incidence of TAVI-related complications or identifying predictors of specific adverse events, for example, paravalvular leak.^{8,9} However, a comprehensive analysis of predictors of 30-day and midterm mortality is still lacking. The aim of this study was thus to identify predictors of post-TAVI 30-day and midterm mortality by means of a systemic review of the currently available literature.

Methods

This study was conducted in accordance with the current guidelines, including the recent Preferred Reporting Items for Systematic reviews and Meta-Analyses amendment to the Quality of Reporting of Meta-analyses statement, and recommendations from The Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology (MOOSE).¹⁰

PubMed and Cochrane databases were searched for reports published in English from January 2002 to June 2013 according to the following highly sensitive strategy, in compliance with established methods and incorporating wildcards (identified by *): (TAVI* OR TAVR OR

“transcatheter aortic”) AND (“adverse events” OR “30 days events” OR “mid-term prognosis”) AND english[lang] AND (“c”[pdat]:“3000”[pdat]) NOT (review[pt] OR editorial[pt] OR letter[pt]).

Retrieved citations were first screened for relevance independently by 2 reviewers (FG and FDA) at the title and/or abstract level. The reports remaining after the initial screening were appraised in the full text with respect to the following inclusion criteria: (1) human study, (2) investigating patients undergoing TAVI, (3) reporting predictors of mortality at 30 days or at midterm follow-up, and (4) online full-text available publication. All criteria had to be met for inclusion. Exclusion criteria were (1) duplicate reporting and (2) study population <50 patients. The presence of even one of the exclusion criteria sufficed for exclusion. Duplicate reporting was handled by selecting the study reporting on the largest sample of patients undergoing TAVI, or if equal, the study with the largest number of overall patients.

The quality and validity of the included studies were independently assessed by 2 reviewers (FG and FDA). After modifying the MOOSE item list, to ensure compatibility with the included studies, each study was summarized and critically appraised with respect to study design, data source, the statistical methods used for multivariate analysis, and the risk of bias (graded as low, moderate, high, or unknown because incomplete reporting may render it impossible to ascertain the risk of bias).¹⁰ Encountered bias was further subdivided into analytical, selection, adjudication, detection, and attrition bias.

Relevant study data were extracted independently by the reviewers (FG and FDA). The extracted data comprised authors and journal names, year of publication, location of

Table 1
Baseline characteristics

First Author	Recruitment Years	Number	Age	Women	DM	NYHA III	CAD*	Previous AMI	Previous Revascularization (Surgical or Percutaneous)	Previous Cardiac Surgery	COPD	GFR <60 ml/min/m ²
Thomas ¹⁷ (2011)	2007e2009	1038	81	576 (56%)	—	146 (14%)	537 (52%)	—	495 (48%)	236 (23%)	286 (28%)	305 (29%)
Kempfert ¹⁸ (2011)	2006e2010	299	82	209 (70%)	115 (52%)	252 (84%)	159 (53%)	8 (3%)	—	86 (29%)	129 (43%)	26 (9%)
Parenica ¹⁹ (2012)	—	29	82	21 (72%)	3 (10%)	26 (90%)	—	—	—	1 (3%)	5 (17%)	—
Halliday ²⁰ (2012)	2008e2010	101	83	52 (51%)	22 (22%)	—	—	—	—	—	—	—
Yong ²¹ (2012)	2007e2011	119	81	72 (61%)	31 (26%)	—	24 (20%)	22 (18%)	41 (34%)	15 (13%)	40 (34%)	—
Barbash ²² (2012)	2007e2011	165	85	96 (58%)	53 (32%)	—	92 (56%)	—	81 (49%)	54 (33%)	45 (69%)	128 (78%)
Sinning ²³ (2012)	2009e2010	1315	82	765 (58%)	462 (35%)	1166 (89%)	791 (60%)	209 (16%)	693 (53%)	289 (22%)	314 (24%)	786 (60%)
Buellesfeld ²⁴ (2012)	2007e2010	353	83	203 (58%)	92 (26%)	263 (75%)	203 (58%)	61 (17%)	151 (43%)	82 (23%)	—	77 (22%)
Humphries ²⁵ (2012)	2005e2011	641	83	329 (51%)	197 (31%)	554 (86%)	467 (73%)	259 (40%)	328 (51%)	—	170 (27%)	413 (64%)
Tchetche ²⁶ (2012)	2010e2011	134	82	53 (40%)	30 (22%)	111 (83%)	56 (42%)	—	56 (42%)	16 (12%)	34 (25%)	37 (28%)
Akin ²⁷ (2012)	2007e2008	45	82	27 (60%)	17 (38%)	43 (91%)	—	—	—	3 (6%)	8 (2%)	25 (56%)
Rodes-Cabau ²⁸ (2012)	2005e2009	339	81	187 (55%)	79 (23%)	308 (90%)	234 (69%)	173 (51%)	215 (63%)	116 (34%)	100 (30%)	—
Latib ²⁹ (2012)	2003e2011	111	81	49 (44%)	21 (19%)	75 (67.6%)	44 (40%)	16 (14%)	—	0	29 (26%)	—
Pilgrim ³⁰ (2012)	2007e2011	389	82	224 (58%)	105 (27%)	—	238 (61%)	64 (17%)	166 (43%)	72 (18%)	72 (19%)	268 (69%)
Hayashida ³¹ (2012)	2006e2011	400	83	206 (52%)	92 (23%)	347 (87%)	237 (59%)	—	—	63 (16%)	124 (31%)	249 (63%)
Généreux ³² (2013)	2008e2011	218	85	106 (48%)	62 (29%)	—	—	—	177 (80%)	89 (40%)	64 (29%)	18 (8%)
Amabile ³³ (2013)	2008e2012	173	84	91 (53%)	43 (25%)	—	107 (63%)	—	—	—	46 (27%)	121 (71%)
Van der Boon ³⁴ (2013)	—	940	81	434 (46%)	268 (29%)	761 (81%)	425 (45%)	158 (17%)	484 (52%)	207 (22%)	323 (34%)	591 (63%)
Toggweiler ³⁵ (2013)	2005e2007	88	87	41 (47%)	22 (25%)	—	63 (72%)	69 (78%)	—	34 (39%)	23 (26%)	47 (53%)
Stortecky ³⁶ (2013)	2007e2011	389	83	224 (58%)	105 (27%)	255 (66%)	238 (61%)	64 (16%)	166 (43%)	72 (19%)	—	268 (69%)
Codner ³⁷ (2013)	2008e2012	153	82	95 (62%)	45 (29%)	149 (87%)	—	11 (7%)	82 (54%)	38 (25%)	43 (28%)	60 (39%)
Borz ³⁸ (2013)	2006e2011	250	83	135 (54%)	64 (26%)	—	87 (35%)	—	—	49 (20%)	—	—
D'Onofrio ³⁹ (2013)	2008e2012	774	81	446 (58%)	205 (27%)	621 (80%)	168 (22%)	23 (3%)	226 (29%)	167 (33%)	247 (32%)	80 (10%)
López-Otero ⁴⁰ (2013)	2008e2011	85	83	31 (37%)	20 (24%)	—	70 (82%)	9 (9%)	—	—	20 (24%)	—
Seiffert ⁴¹ (2013)	2008e2011	326	81	181 (56%)	—	266 (82%)	201 (62%)	65 (20%)	180 (55%)	65 (20%)	87 (27%)	29 (9%)

AMI ¼ acute myocardial infarction; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; DM ¼ diabetes mellitus; GFR ¼ glomerular filtration rate; NYHA ¼ New York Heart Association.

* Defined as coronary stenosis >50%.

Table 2
Echocardiographic and procedural features

First Author	LVEF	Aortic Valve MG	MR >2+	Pulmonary Hypertension	TF	TA	TS	TAo	EDW	CV	Log ES	STS Score
Thomas ¹⁷ (2011)	—	—	257 (25%)	—	463 (45%)	575 (55%)	0	0	1038 (100%)	0	28	—
Kempfert ¹⁸ (2011)	55 13	—	3 (1%)	81 (27%)	0	299 (100%)	—	—	299 (100%)	0	31 16	13 8
Parenica ¹⁹ (2012)	57	50	—	11 (38%)	14 (25%)	15 (26%)	—	—	29 (100%)	0	24	—
Halliday ²⁰ (2012)	—	—	—	—	45 (45%)	56 (55%)	0	0	—	—	22 0.9	—
Yong ²¹ (2012)	—	49 16	10 (8%)	—	119 (100%)	0	0	0	0	119 (100%)	19 13	6 5
Barbash ²² (2012)	51 15	—	—	—	117 (71%)	48 (29%)	0	—	—	—	—	12 4
Sinning ²³ (2012)	52 15	—	—	—	1143 (87%)	121 (9%)	41 (3%)	10 (1%)	—	—	21 14	—
Buellesfeld ²⁴ (2012)	50	44	—	88 (25%)	353 (100%)	0	0	0	34 (10%)	319 (90%)	26	—
Humphries ²⁵ (2012)	—	41	166 (26%)	—	351 (55%)	290 (45%)	0	0	622 (97%)	19 (3%)	—	8
Tchetche ²⁶ (2012)	47 13	48 15	0	—	125 (93%)	0	9 (7%)	0	0	134 (100%)	24 10	—
Akin ²⁷ (2012)	48	57	41 (85%)	—	45 (100%)	—	—	—	45 (100%)	—	21	—
Rodes-Cabau ²⁸ (2012)	55 14	—	27 (8%)	84 (25%)	163 (48%)	176 (52%)	0	0	339 (100%)	0	—	10 6
Latib ²⁹ (2012)	54 13	—	—	—	111 (100%)	0	0	0	70 (63%)	41 (37%)	23 15	4.6 2.3
Pilgrim ³⁰ (2012)	52 15	44 17	—	111 (31%)	308 (80%)	76 (20%)	5 (1%)	0	164 (42%)	225 (58%)	24 14	6.8 5.3
Hayashida ³¹ (2012)	—	—	—	—	—	—	—	—	347 (87%)	53 (13%)	22	8
Généreux ³² (2013)	48 16	45 15	—	—	140 (64%)	78 (36%)	0	0	218 (100%)	0	—	12 5
Amabile ³³ (2013)	55 15	49 18	—	—	139 (81%)	32 (19%)	0	0	132 (77%)	39 (23%)	22 12	—
Van der Boon ³⁴ (2013)	—	—	—	—	79 (84%)	89 (10%)	57 (6%)	4 (0.4%)	435 (46%)	505 (54%)	21	—
Toggweiler ³⁵ (2013)	60	46 18	—	17 (19%)	64 (73%)	24 (27%)	0	0	88 (100%)	0	—	9
Stortecky ³⁶ (2013)	52 15	44 17	—	—	308 (79%)	76 (20%)	5 (1%)	0	165 (42%)	224 (58%)	24 14	7 5
Codner ³⁷ (2013)	—	51 15	52 (33%)	—	112 (73%)	27 (18%)	13 (9%)	1 (1%)	62 (41%)	91 (60%)	23 13	9 5
Borz ³⁸ (2013)	—	45 17	—	—	190 (76%)	60 (24%)	0	0	250 (100%)	0	23 13	—
D'Onofrio ³⁹ (2013)	53 13	50 15	173 (22%)	87 (11%)	0	774 (100%)	0	0	774 (100%)	0	26 16	10 8
López-Otero ⁴⁰ (2013)	—	—	—	—	—	0	—	0	0	85 (100%)	29 8	—
Seiffert ⁴¹ (2013)	—	37 2	30 (9%)	48 (19%)	149 (45%)	177 (51%)	0	0	281 (81%)	45 (13%)	23 2	8 1

CV ¼ CoreValve; EDW ¼ Edwards Sapien; ES ¼ EuroSCORE; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; STS ¼ Society of Thoracic Surgery; TA ¼ transapical; Tao ¼ transaortic; TF ¼ transfemoral; TS ¼ trans-subclavian.




Figure 2. Independent predictors of 30-day mortality at 1 year with OR >5.




Figure 3. Independent predictors of all-cause mortality at midterm follow-up with OR >5.

Table 3
Meta-regression of baseline features on all-cause death at follow-up

	Beta	LCI	UCI	p
Age	0.16	0.24	0.32	0.09
Female gender	0.001	0.37	0.45	0.90
Diabetes mellitus	0.004	0.006	0.004	0.61
NYHA class more than III	0.01	0.005	0.02	0.04
Coronary artery disease	0.03	0.04	0.06	0.89
COPD	0.06	0.08	0.10	0.75
Reduced renal function	0.10	0.01	0.12	0.88

COPD ¼ chronic obstructive pulmonary disease; LCI ¼ low confidence interval; NYHA ¼ New York Heart Association; UCI ¼ upper confidence interval.

the study group, baseline patient characteristics, procedural features, and multivariate predictors of all-cause mortality (estimator, point summary estimate of risk, 95% confidence intervals [CIs]). End points of interest for the present review were the incidence of TAVI-related complications and 30-day and midterm all-cause mortality. Multivariate predictors with an odds ratio (OR) >5 reported in at least 3 studies were reported. Meta-regression analysis was performed for midterm all-cause mortality for baseline clinical variables.

Result analysis of the studies was registered on dedicated electronic forms. The forms were piloted over the first 5




Figure 4. Regression of NYHA class >III on logistic event rate.

cases for consistency and discrimination. Any divergence in opinion between the reviewers at any stage of the review process was resolved by consensus discussion.

Continuous variables are reported as mean SD or median and range. Categorical variables are expressed as counts and percentages. Independent predictors of TAVI-related complications and 30-day and midterm all-cause mortality were appraised and ordered according to their measure of risk (either OR or hazard ratio) with Review Manager (RevMan), version 5.2, freeware package (The Cochrane Collaboration, The Nordic Cochrane Center, Copenhagen, Denmark) and Comprehensive Meta-Analysis. Small study bias was appraised by graphical inspection of funnel plots. Hypothesis testing for superiority was set at the 2-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the 2-tailed 0.10 level and based on the Cochran Q test, with I² values of 25%, 50%, and 75% representing, respectively, mild, moderate, and extensive statistical inconsistency.

Results

The search strategy yielded 1,088 reports. Four reports derived from congresses were added, resulting in a total of 1,092 citations. All citations were first screened at title and abstract level; the 31 remaining reports were subsequently screened full text. Of the full-text analyzed citations, 4 were excluded because of reporting duplicate data^{11e14} and 2 because of the absence of data on independent predictors for

adverse events.^{15,16} Twenty-five studies were finally included in this systemic review (Figure 1).^{17e41}

The 25 included studies reported on a total of 8,874 patients treated with TAVI for symptomatic severe aortic stenosis (AS). Approximately 1/2 of the patients were women (54.6%); median age was 82.5 ± 1.5 years. Mean logistic EuroSCORE-I was 23.4 ± 3.1% and was above 20% in all studies, except for one (19 ± 13%).²¹ In those studies (n ¼ 5) in which reporting results was exclusively done using the Society of Thoracic Surgery score,^{22,25,28,32,35} the mean risk of perioperative mortality was >5%. Diabetes mellitus was present in 24% (n ¼ 2,153) of patients, renal insufficiency in 48% (n ¼ 4,264), and a history of previous revascularization (either surgical or percutaneous) in 40% (n ¼ 3,541). Left ventricular ejection fraction (LVEF) was in general preserved, except for 3 studies in which mean LVEF was mildly compromised (range of mean LVEF 47% to 60%).^{26,27,32} The most important baseline characteristics are reported in Table 1.

A small majority of patients were treated by the transfemoral approach (51.1%), followed by the transapical approach (33.7%), and only few patients received a direct aortic or trans-subclavian procedure (1.5% and 0.2%, respectively). In 60.8% (n/4 5,392) of patients, an Edwards SAPIEN or SAPIEN XT balloon-expandable valve (both Edwards Lifesciences, Irvine, California) was implanted, and in 21.4% (n/4 1,899) of patients, the self-expandable third-generation Medtronic CoreValve (Medtronic Inc., Minneapolis, Minnesota) prostheses were used, whereas 3 studies (comprising 15.8% of patients, n/4 1,583) did not specify the type of valve implanted.^{20,22,23} Because of the infrequent reporting of conversion to surgery and intra-procedural death, no reliable incidence could be reported for these events. Table 2 summarizes procedural TAVI characteristics in the various studies.

At 30 days, 7.5% (n/4 663) of patients died. Acute kidney injury (AKI) occurred in 8.02% (n/4 712), life-threatening and major bleeding in 13.8% (n/4 1,224), major vascular complications in 8.8% (n/4 782), periprocedural acute myocardial infarction (AMI) in 0.6% (n/4 51), and pacemaker implantation in 12.5% (n/4 1,106) of patients. At midterm follow-up (median 365 days, interquartile range 267 to 365), 21.6% (n/4 1,917) of patients had died. The strongest predictors of 30-day mortality were AKI stage 2 (OR 18.0, 95% CI 6.25 to 52), preprocedural hospitalization for at least 1 week (OR 9.36, 95% CI 2.55 to 35), periprocedural AMI (OR 8.54, 95% CI 2.57 to 33.52), and preprocedural increased pro-brain natriuretic peptide (pro-BNP) levels (OR 5.35, 95% CI 1.74 to 16.5; Figure 2). The most important predictors for cumulative midterm mortality were increased pro-BNP levels (OR 11, 95% CI 1.51 to 81), AKI stage 3 (OR 6.80, 95% CI 2.55 to 15.66), LVEF <30% (OR 6.67, 95% CI 3.5 to 12.76), and periprocedural AMI (OR 6.52, 95% CI 2.34 to 18.14; Figure 3).

At meta-regression analysis, similarly, NYHA class >III was related to all-cause midterm mortality (Table 3 and Figure 4).

Discussion

Profound understanding of factors determining patient survival after TAVI is of paramount importance in clinical practice not only to enable to accurately select patients, that is, only those in whom treatment benefit outweighs the risk, but also to take appropriate measures to prevent complications in high-risk subjects, especially considering that the commonly used logistic EuroSCORE falls short in predicting mortality, as it does not take account of periprocedural events, and it is known to overestimate operative risk in patients undergoing TAVI.⁷

This is the largest systematic review to assess predictors

of periprocedural and long-term mortality in high-risk and highly symptomatic patients with severe AS from all over the world, undergoing TAVI treatment from 2003 to 2012, and thus represents a wide range of TAVI experience. The 30-day and midterm mortality rates in this large group of patients were 7.5% and 21.6%, respectively, signifying that nearly 30% of deaths occurred within the first 30 days after TAVI, well in line with data previously reported by several real-world registries and 1 meta-analysis.^{42,43}

Based on Valvular Academic Research Consortium 1 criteria, the strongest predictor for 30-day mortality was stage 2 AKI, whereas stage 3 AKI was an important determinant of midterm mortality. The reported incidence of AKI after percutaneous valve implantation varies from 8% to 28%,^{32,44e47} mainly because of differences in AKI definition, which is considerably lower than that observed after cardiac surgery.⁴⁸ Many patients actually demonstrate an improvement of renal function after TAVI rather than kidney injury, as abolishment of the valvular obstruction leads to improved renal hemodynamics.⁴⁴ Several factors are believed to be involved in the undesired development of AKI. Intra-procedural episodes of hypotension and emboli generated by catheter manipulations, balloon valvuloplasty and/or prosthesis deployment, and postprocedural bleedings might result in tubular ischemia and consequential decrease in kidney function.^{46,47} Moreover, the occurrence of paravalvular aortic regurgitation produces acute volume overload with a subsequent increase in left ventricular end-diastolic pressure, ultimately leading to a reduction in diastolic renal blood flow and impairment of renal function.⁴⁶ The fact that AKI is most strongly associated with short-term mortality, also shown in the present review, supports this hypothesis.

Preprocedural elevated pro-BNP levels (measured 24 hours before TAVI) were also a strong independent predictor of both 30-day and midterm mortality. The prognostic value of natriuretic peptides was previously recognized in interventions on the aortic valve.^{49,50} Likewise, baseline BNP and pro-BNP levels have been identified as independent predictors of 30-day and long-term mortality in TAVI, respectively.^{49e52} The unfavorable outcome of valve interventions in patients with high BNP levels is believed to be related to the presence of impaired systolic and/or diastolic left ventricular function, as both types of myocardial dysfunction are associated with elevated BNP levels.⁴⁹ Patients with high preprocedural BNP might benefit from optimization of their hemodynamic status by bridging therapy (optimization of medical therapy or balloon valvuloplasty) before proceeding to TAVI, although further research is warranted to confirm this.

Not surprisingly, preprocedural hospitalization (mainly for decompensated AS) and preprocedural LVEF 30% were among the strongest predictors of 30-day and midterm mortality, respectively. This finding reflects, on one hand, the severity of AS disease and, on the other hand, a poorer functional status, characterizing the more frail patients. Moreover, recent research revealed that clinically inoperable patients, a designation often based on frailty, have worse survival compared with technically inoperable patients.⁵²

Finally, periprocedural myocardial injury and infarction were among the strongest predictors of post-TAVI mortality in this analysis. TAVI is systematically associated with myocardial injury, as an increase in the troponin level above the URL is observed in nearly all patients.^{21,53,54} A single study demonstrated a strong association between biomarker-determined myocardial injury (defined as peak values of cardiac troponin T and/or creatine kinase-MB >5 times the URL, not fulfilling the criteria for myocardial infarction) and 30-day and 1-year survival rates.⁵⁴ Myocardial injury during TAVI is most likely caused by global myocardial

ischemia, resulting from a mismatch in myocardial oxygen supply and demand. The diffuse nature of myocardial injury makes it unlikely to cause left ventricular dysfunction with subsequent heart failure or myocardial scarring prone to ventricular arrhythmia. Therefore, it was hypothesized that myocardial injury is a marker for more extensive (vascular) disease, which may increase the risk for postprocedural adverse events.²¹ Periprocedural myocardial infarction, defined by the additional development of new Q waves and/or wall motion abnormalities according to the Valvular Academic Research Consortium criteria, is a rare finding estimated to occur in approximately 1% of TAVI cases.^{21,53e55} In this review, it was identified as one of the

strongest predictors of midterm mortality.

There was a great deal of overlap between the strongest predictors of 30-day and cumulative midterm mortality in the present work. This might originate from true shared predictors of both events, or it might reflect an overwhelming effect of 30-day mortality on the analysis of predictors for cumulative midterm death rates. The most powerful preprocedural predictors (elevated BNP, preprocedural hospitalization, and reduced LVEF) of mortality were predominantly related to AS disease severity, suggesting that timely reference for TAVI might be vital to increase the odds of postprocedural survival. All the postprocedural predictors (AKI and AMI) were associated with TAVI complications, emphasizing the importance of preventing these events.^{56,57}

In this systematic review, the strongest independent predictors of 30-day and cumulative midterm mortality were identified by means of their measured effect size (expressed by their OR or hazard ratio). The reporting of predictors was therefore entirely determined by an arbitrarily set OR threshold of 5.0, meaning that less-influential predictors were not presented. These include predictors that might be of clinical importance based on their prevalence in the population with TAVI, rather than their effect size. The results of this study should be interpreted in the light of this notion.

Furthermore, the literature referred to in this review represents a considerable range of TAVI experience, institutional routines, follow-up durations, and complication definitions. The present analysis did not take into account this heterogeneity of the included studies, potentially hampering the generalizability of the results. Moreover, the validity of the multivariate analyses that yielded the independent predictors heavily depends on whether all potential predictors were measured and included in the model, as multivariate analysis does not consider unmeasured variables. Finally, the present review is a not patient level-based analysis, consequently limiting methodological relevance of the present work. The assessment of external and internal validity of the separate studies was solely used to select the studies; the reported results were not weighed accordingly.

Disclosures

The authors have no conflicts of interest to disclose.

1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC,

- Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;363:1597e1607.
2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;364:2187e2198.
3. Indraratna P, Ang SC, Gada H, Yan TD, Manganas C, Bannon P, Cao C. Systematic review of the cost-effectiveness of transcatheter aortic valve implantation. *J Thorac Cardiovasc Surg* 2013 [Epub ahead of

- print].
4. Van Brabant H, Neyt M, Hulstaert F. Transcatheter aortic valve implantation (TAVI): risky and costly. *BMJ* 2012;345:e4710.
5. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). *Eur J Cardiothorac Surg* 1999;16:9e13.
6. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, Ferguson TB Jr, Grover FL, Edwards FH; Society of Thoracic Surgeons. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. *Ann Thorac Surg* 2003;75:1856e1864.
7. D'Ascenzo F, Ballocca F, Moretti C, Barbanti M, Gasparetto V, Mennuni M, D'Amico M, Conrotto F, Salizzoni S, Omedè P, Colaci C, Zoccai GB, Lupo M, Tarantini G, Napodanno M, Presbitero P, Sheiban I, Tamburino C, Marra S, Gaita F. Inaccuracy of available surgical risk scores to predict outcomes after transcatheter aortic valve replacement. *J Cardiovasc Med (hagerstown)* 2013;14:894e895.
8. Khatri PJ, Webb JG, Rodés-Cabau J, Fremes SE, Ruel M, Lau K, Guo H, Wijeyesundera HC, Ko DT. Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. *Ann Intern Med* 2013;158:35e46.
9. Athappan G, Patvardhan E, Tuzcu EM, Svensson LG, Lemos PA, Fracarro C, Tarantini G, Sinning JM, Nickenig G, Capodanno D, Tamburino C, Latib A, Colombo A, Kapadia SR. Incidence, predictors and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. *J Am Coll Cardiol* 2013;61:1585e1595.
10. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
11. Hayashida K, Bouvier E, Lefèvre T, Hovasse T, Morice MC, Chevalier B, Romano M, Garot P, Mylotte D, Farge A, Donzeau-Gouge P, Cormier B. Impact of CT-guided valve sizing on post-procedural aortic regurgitation in transcatheter aortic valve implantation. *Euro-Intervention* 2012;8:546e555.
12. Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Feindel CM, Osten M, Natarajan MK, Velianou JL, Martucci G, DeVarennes B, Chisholm R, Peterson MD, Lichtenstein SV, Nieltispach F, Doyle D, DeLarochellière R, Teoh K, Chu V, Dancea A, Lachapelle K, Cheema A, Latter D, Horlick E. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol* 2010;55:1080e1090.
13. Chieffo A, Buchanan GL, Van Mieghem NM, Tchetché D, Dumonteil N, Latib A, van der Boon RM, Vahdat O, Marcheix B, Farah B, Serruys PW, Fajadet J, Carrié D, de Jaegere PP, Colombo A. Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-Rotterdam-Milano-Toulouse In Collaboration). *J Am Coll Cardiol* 2013;61:830e836.
14. Van Mieghem NM, Chieffo A, Dumonteil N, Tchetché D, van der Boon RM, Buchanan GL, Marcheix B, Vahdat O, Serruys PW, Fajadet J, Carrié D, Colombo A, de Jaegere PP. Trends in outcome after transfemoral transcatheter aortic valve implantation. *Am Heart J* 2013;165:183e192.
15. Dworakowski R, Wendler O, Bhan A, Smith L, Pearson P, Alcock E, Rajagopal K, Brickham B, Dew T, Byrne J, Monaghan MJ, Sherwood R, Shah AM, MacCarthy PA. Successful transcatheter aortic valve

792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852

- implantation (TAVI) is associated with transient left ventricular dysfunction. *Heart* 2012;98:1641e1646.
16. Vasa-Nicotera M, Sinning JM, Chin D, Lim TK, Spyt T, Jilaihawi H, Grube E, Werner N, Nickenig G, Kovac J. Impact of paravalvular leakage on outcome in patients after transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2012;5:858e865.
 17. Thomas M, Schymik G, Walther T, Himbert D, Lefèvre T, Treede H, Eggebrecht H, Rubino P, Colombo A, Lange R, Schwarz RR, Wendler O. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. *Circulation* 2011;124:425e433.
 18. Kempfert J, Rastan A, Holzhey D, Linke A, Schuler G, van Linden A, Blumenstein J, Mohr FW, Walther T. Transapical aortic valve implantation: analysis of risk factors and learning experience in 299 patients. *Circulation* 2011;124:S124e129.
 19. Parenica J, Nemeš P, Tomandl J, Ondrasek J, Pavkova-Goldbergova M, Tretina M, Jarkovsky J, Littnerova S, Poloczek M, Pokorny P, Spinar J, Cermakova Z, Miklik R, Malik P, Pes O, Lipkova J, Tomandlova M, Kala P. Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation. *PLoS One* 2012;7:e48851.
 20. Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. *Am J Cardiol* 2012;109:724e728.
 21. Yong ZY, Wiegerinck EM, Boerlage-van Dijk K, Koch KT, Vis MM, Bouma BJ, Henriques JP, Cocchieri R, Piek JJ, de Mol BA, Baan J Jr. Predictors and prognostic value of myocardial injury during transcatheter aortic valve implantation. *Circ Cardiovasc Interv* 2012;5:415e423.
 22. Barbash IM, Ben-Dor I, Dvir D, Maluenda G, Xue Z, Torguson R, Satler LF, Pichard AD, Waksman R. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. *Am Heart J* 2012;163:1031e1036.
 23. Sinning JM, Horack M, Grube E, Gerckens U, Erbel R, Eggebrecht H, Zahn R, Linke A, Sievert H, Figulla HR, Kuck KH, Hauptmann KE, Hoffmann E, Hambrecht R, Richardt G, Sack S, Senges J, Nickenig G, Werner N. The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation: results from the German Transcatheter Aortic Valve Interventions Registry. *Am Heart J* 2012;164:102e110.
 24. Buellesfeld L, Stortecky S, Heg D, Hausen S, Mueller R, Wenaweser P, Pilgrim T, Gloekler S, Khattab AA, Huber C, Carrel T, Eberle B, Meier B, Boekstegers P, Jüni P, Gerckens U, Grube E, Windecker S. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. *J Am Coll Cardiol* 2012;60:493e501.
 25. Humphries KH, Toggweiler S, Rodés-Cabau J, Nombela-Franco L, Dumont E, Wood DA, Willson AB, Binder RK, Freeman M, Lee MK, Gao M, Izadnegahdar M, Ye J, Cheung A, Webb JG. Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. *J Am Coll Cardiol* 2012;60:882e886.
 26. Tchetché D, Modine T, Farah B, Vahdat O, Sudre A, Koussa M, Lereun C, Nejari M, Choby M, Rosencher J, Sorbets E, Fajadet J. Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve Accutrak system. *EuroIntervention* 2012;8:556e562.
 27. Akin I, Kische S, Paranskaya L, Schneider H, Rehders TC, Trautwein U, Turan G, Bänsch D, Thiele O, Divchev D, Bozdog-Turan I, Ortak J, Kundt G, Nienaber CA, Ince H. Predictive factors for pacemaker requirement after transcatheter aortic valve implantation. *BMC Cardiovasc Disord* 2012;12:87.
 28. Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Osten M, Feindel CM, Natarajan MK, Velianou JL, Martucci G, DeVarennes B, Chisholm R, Peterson M, Thompson CR, Wood D, Toggweiler S, Gurvitch R, Lichtenstein SV, Doyle D, DeLarochellière R, Teoh K, Chu V, Bainey K, Lachapelle K, Cheema A, Latter D, Dumesnil JG, Pibarot P, Horlick E. Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. *J Am Coll Cardiol* 2012;60:1864e1875.
 29. Latib A, Maisano F, Bertoldi L, Giacomini A, Shannon J, Cioni M, Ielasi A, Figini F, Tagaki K, Franco A, Covello RD, Grimaldi A, Spagnolo P, Buchanan GL, Carlino M, Chieffo A, Montorfano M, Alfieri O, Colombo A. Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: a propensity score-matched case-control study. *Am Heart J* 2012;164:910e917.
 30. Pilgrim T, Kalesan B, Wenaweser P, Huber C, Stortecky S, Buellesfeld L, Khattab AA, Eberle B, Gloekler S, Gsponer T, Meier B, Jüni P, Carrel T, Windecker S. Predictors of clinical outcomes in patients with severe aortic stenosis undergoing TAVI: a multistate analysis. *Circ Cardiovasc Interv* 2012;5:856e861.
 31. Hayashida K, Lefèvre T, Chevalier B, Hovasse T, Romano M, Garot P, Bouvier E, Farge A, Donzeau-Gouge P, Cormier B, Morice MC. Impact of post-procedural aortic regurgitation on mortality after transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2012;5:1247e1256.
 32. Gèneux P, Kodali SK, Green P, Paradis JM, Daneault B, Rene G, Hueter I, Georges I, Kirtane A, Hahn RT, Smith C, Leon MB, Williams MR. Incidence and effect of acute kidney injury after transcatheter aortic valve replacement using the new valve academic research consortium criteria. *Am J Cardiol* 2013;111:100e105.
 33. Amabile N, Azmoun A, Ghostine S, Ramadan R, Haddouche Y, Raoux F, To NT, Troussier X, Nottin R, Caussin C. Incidence, predictors and prognostic value of serious hemorrhagic complications following transcatheter aortic valve implantation. *Int J Cardiol* 2013;168:151e156.
 34. Van der Boon RM, Chieffo A, Dumontel N, Tchetché D, Van Mieghem NM, Buchanan GL, Vahdat O, Marcheix B, Serruys PW, Fajadet J, Colombo A, Carrié D, van Domburg RT, de Jaegere PP, PRAGMATIC-Plus Researchers. Effect of body mass index on short- and long-term outcomes after transcatheter aortic valve implantation. *Am J Cardiol* 2013;111:231e236.
 35. Toggweiler S, Humphries KH, Lee M, Binder RK, Moss RR, Freeman M, Ye J, Cheung A, Wood DA, Webb JG. 5-year outcome after transcatheter aortic valve implantation. *J Am Coll Cardiol* 2013;61:413e419.
 36. Stortecky S, Buellesfeld L, Wenaweser P, Heg D, Pilgrim T, Khattab AA, Gloekler S, Huber C, Nietlispach F, Meier B, Jüni P, Windecker S. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. *Circ Cardiovasc Interv* 2013;6:77e84.
 37. Codner P, Assali A, Dvir D, Vaknin-Assa H, Porat E, Shapira Y, Kupersmidt M, Bental T, Battler A, Sagie A, Kornowski R. Two-year outcomes for patients with severe symptomatic aortic stenosis treated with transcatheter aortic valve implantation. *Am J Cardiol* 2013;111:1330e1336.
 38. Borz B, Durand E, Godin M, Tron C, Canville A, Litzler PY, Bessou JP, Cribier A, Eltchaninoff H. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. *Heart* 2013;99:860e865.
 39. D'Onofrio A, Rubino P, Fusari M, Salvador L, Musumeci F, Rinaldi M, Vitali EO, Glauber M, Di Bartolomeo R, Alfieri OR, Polesel E, Aiello M, Casabona R, Livi U, Grossi C, Cassese M, Pappalardo A, Gherli T, Stefanelli G, Faggian GG, Gerosa G. Clinical and hemodynamic outcomes of "all-comers" undergoing transapical aortic valve implantation: results from the Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA). *J Thorac Cardiovasc Surg* 2011;142:768e775.
 40. López-Otero D, Trillo-Nouche R, Gude F, Cid-Álvarez B, Ocaranza-Sanchez R, Alvarez MS, Lear PV, Gonzalez-Juanatey JR. Pro B-type natriuretic peptide plasma value: a new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation. *Int J Cardiol* 2013;168:1264e1268.
 41. Seiffert M, Schnabel R, Conradi L, Diemert P, Schirmer J, Koschky D, Linder M, Kersten JF, Grosser A, Wilde S, Blankenberg S, Reichenspurner H, Baldus S, Treede H. Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the Valve Academic Research Consortium definitions. *Catheter Cardiovasc Interv* 2013;82:640e652.
 42. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D, Tchetché D, Carrié D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J, Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B,

- 975 Van Belle E, Laskar M. Registry of transcatheter aortic-valve im- 1049
 976 plantation in high-risk patients. *N Engl J Med* 2012;366:1705e1715. 1050
 977 43. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint defini- 1051
 978 tions for transcatheter aortic valve implantation clinical trials: a 1052
 979 consensus report from the Valve Academic Research Consortium. *Eur 1053*
 980 **Q8** *Heart J* 2011;32:205e217. 1054
 981 44. Loeff BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, 1055
 982 Stegeman CA. Immediate postoperative renal function deterioration in 1056
 983 cardiac surgical patients predicts in-hospital mortality and long-term 1057
 984 survival. *J Am Soc Nephrol* 2005;16:195e200. 1058
 985 45. D'Ascenzo F, Moretti C, Salizzoni S, Bollati M, D'Amico M, Ballocca 1059
 986 F, Giordana F, Barbanti M, Ussia GP, Brambilla N, Bedogni F, Biondi 1060
 987 Zoccai G, Tamburino C, Gaita F, Sheiban I. 30 days and midterm 1061
 988 outcomes of patients undergoing percutaneous replacement of aortic 1062
 989 valve according to their renal function: a multicenter study. *Int J 1063*
 990 *Cardiol* 2013;167:1514e1518. 1064
 991 46. Moretti C, D'Amico M, D'Ascenzo F, Colaci C, Salizzoni S, 1065
 992 Tamburino C, Presbitero P, Marra S, Sheiban I, Gaita F. Impact on 1066
 993 prognosis of periprocedural bleeding after TAVI: mid-term follow-up 1067
 994 of a multicenter prospective study. *J Interv Cardiol* 2014;27: 1068
 995 293e299. 1069
 996 47. D'Ascenzo F, Gonella A, Moretti C, Omedè P, Salizzoni S, La Torre 1070
 997 M, Giordana F, Barbanti M, Ussia GP, Brambilla N, Bedogni F, Gaita 1071
 998 F, Tamburino C, Sheiban I. Gender differences in patients undergoing 1072
 999 TAVI: a multicentre study. *EuroIntervention* 2013;9:367e372. 1073
 1000 48. Sreeram GM, Grocott HP, White WD, Newman MF, Stafford-Smith 1074
 1001 M. Transcranial Doppler emboli count predicts rise in creatinine after 1075
 1002 coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 1076
 1003 2004;18:548e551. 1077
 1004 49. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel 1078
 1005 H, Binder T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides 1079
 1006 predict symptom-free survival and postoperative outcome in severe 1080
 1007 aortic stenosis. *Circulation* 2004;109:2302e2308. 1081
 1008 50. D'Ascenzo F, Conrotto F, Giordana F, Moretti C, D'Amico M, Sal- 1082
 1009 izzoni S, Omedè P, La Torre M, Thomas M, Khawaja Z, Hildick-Smith 1083
 1010 D, Ussia G, Barbanti M, Tamburino C, Webb J, Schnabel RB, Seiffert 1084
 1011 M, Wilde S, Treede H, Gasparetto V, Napodano M, Tarantini G, 1085
 1012 Presbitero P, Mennuni M, Rossi ML, Gasparini M, Biondi Zoccai G, 1086
 1013 Lupo M, Rinaldi M, Gaita F, Marra S. Mid-term prognostic value of 1087
 1014 coronary artery disease in patients undergoing transcatheter aortic valve 1088
 1015 implantation: a meta-analysis of adjusted observational results. *Int J 1089*
 1016 *Cardiol* 2013;168:2528e2532. 1090
 1017 51. Buellesfeld L, Wenaweser P, Gerckens U, Mueller R, Sauren B, Lat- 1091
 1018 sios G, Zickmann B, Hellige G, Windecker S, Grube E. Transcatheter 1092
 1019 aortic valve implantation: predictors of procedural success—the Sieg- 1093
 1020 burgeBern experience. *Eur Heart J* 2010;31:984e991. 1094
 1021 52. Makkar RR, Jilaihawi H, Mack M, Chakravarty T, Cohen DJ, Cheng 1095
 1022 W, Fontana G, Bavaria J, Thourani V, Herrmann H, Pichard A, 1096
 1023 Kapadia S, Babiliarios V, Whisenant B, Kodali S, Williams M, Trento 1097
 1024 A, Smith C, Teirstein P, Cohen MG, Xu K, Tuzcu EM, Webb J, Leon 1098
 1025 M. Stratification of outcomes after transcatheter aortic valve replace- 1099
 1026 ment according to surgical inoperability for technical versus clinical 1100
 1027 reasons. *J Am Coll Cardiol* 2014;6:901e911. 1101
 1028 53. Carrabba N, Valenti R, Migliorini A, Vergara R, Parodi G, Antoniucci 1102
 1029 D. Prognostic value of myocardial injury following transcatheter aortic 1103
 1030 valve implantation. *Am J Cardiol* 2013;111:1475e1481. 1104
 1031 54. Rodes-Cabau J, Gutiérrez M, Bagur R, De Larochelliere R, Doyle D, 1105
 1032 Cote M, Villeneuve J, Bertrand OF, Larose E, Manazzoni J, Pibarot P, 1106
 1033 Dumont E. Incidence, predictive factors, and prognostic value of 1107
 1034 myocardial injury following uncomplicated transcatheter aortic valve 1108
 1035 implantation. *J Am Coll Cardiol* 2011;57:1988e1999. 1109
 1036 55. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in 1110
 1037 acute aortic regurgitation. *J Am Coll Cardiol* 1995;25:1387e1392. 1111
 1038 56. Di Mario C, Eltchaninoff H, Moat N, Goicolea J, Ussia GE, Kala P, 1112
 1039 Wenaweser P, Zembala M, Nickenig G, Alegria Barrero E, Snow T, 1113
 1040 lung B, Zamorano P, Schuler G, Corti R, Alfieri O, Prendergast B, 1114
 1041 Ludman P, Windecker S, Sabate M, Gilard M, Witowski A, Danenberg 1115
 1042 H, Schroeder E, Romeo F, Macaya C, Derumeaux G, Maggioni A, 1116
 1043 Tavazzi L. The 2011-12 pilot European Sentinel registry of trans- 1117
 1044 catheter aortic valve implantation: in-hospital results in 4,571 patients. 1118
 1045 *EuroIntervention* 2013;8:1362e1371. 1119
 1046 57. Conrotto F, D'Ascenzo F, Giordana F, Salizzoni S, Tamburino C, 1120
 1047 Tarantini G, Presbitero P, Barbanti M, Gasparetto V, Mennuni M, 1121
 1048 Napodano M, Rossi ML, La Torre M, Ferraro G, Omedè P, Scacciatella 1122
 1049 P, Marra WG, Colaci C, Biondi-Zoccai G, Moretti C, D'Amico M, 1123
 1050 Rinaldi M, Gaita F, Marra S. Impact of diabetes mellitus on early and 1124
 1051 midterm outcomes after transcatheter aortic valve implantation (from a 1125
 1052 multicenter registry). *Am J Cardiol* 2014;113:529e534. 1126